Skip to main content
Full access
Regular Articles
Published Online: 1 October 2013

Association of Major Depression With Sexual Dysfunction in Men

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

Abstract

Sexual dysfunction rates were higher for major depressive disorder than for atypical depression. Depression affected sexual function domains differently: orgasm was most impaired, whereas sexual desire was preserved. More severe depression resulted in greater sexual dysfunction.

Abstract

The effect of type and severity of depression on sexual functioning was examined before treatment in 591 men with Major Depression (MDD) or Atypical Depression, as determined by percentage of subjects meeting Diagnostic and Statistical Manual, 4th Edition (DSM-IV) sexual dysfunction criteria (A and B only), and percentage with Derogatis Inventory of Sexual Function (DISF) scores greater than 1 standard deviation below normal. Sexual dysfunction rates were higher for MDD than for Atypical Depression. Depression affected DISF domains differently: orgasm was most impaired, whereas sexual desire was preserved. More severe depression resulted in greater sexual dysfunction.

Formats available

You can view the full content in the following formats:

Supplementary Material

Supplemental Material (308_ds001.pdf)

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 308 - 318
PubMed: 23645187

History

Received: 6 January 2012
Revision received: 8 November 2012
Accepted: 11 December 2012
Published online: 1 October 2013
Published in print: Fall 2013

Authors

Affiliations

Louis F. Fabre, M.D., Ph.D.
From Fabre-Kramer Pharmaceuticals, Houston, TX (LFF, LCS); Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville VA (AHC); San Diego Sexual Medicine, Alvarado Hospital, San Diego CA (IMG); Sheppard Pratt Hospital, Baltimore MD (LRD).
Anita H. Clayton, M.D.
From Fabre-Kramer Pharmaceuticals, Houston, TX (LFF, LCS); Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville VA (AHC); San Diego Sexual Medicine, Alvarado Hospital, San Diego CA (IMG); Sheppard Pratt Hospital, Baltimore MD (LRD).
Louis C. Smith, Ph.D.
From Fabre-Kramer Pharmaceuticals, Houston, TX (LFF, LCS); Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville VA (AHC); San Diego Sexual Medicine, Alvarado Hospital, San Diego CA (IMG); Sheppard Pratt Hospital, Baltimore MD (LRD).
Irwin M. Goldstein, M.D.
From Fabre-Kramer Pharmaceuticals, Houston, TX (LFF, LCS); Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville VA (AHC); San Diego Sexual Medicine, Alvarado Hospital, San Diego CA (IMG); Sheppard Pratt Hospital, Baltimore MD (LRD).
Leonard R. Derogatis, Ph.D.
From Fabre-Kramer Pharmaceuticals, Houston, TX (LFF, LCS); Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville VA (AHC); San Diego Sexual Medicine, Alvarado Hospital, San Diego CA (IMG); Sheppard Pratt Hospital, Baltimore MD (LRD).

Notes

Send correspondence to Dr. Fabre; e-mail: [email protected]

Funding Information

Louis F. Fabre, M.D., Ph.D.: employee of and shareholder in Fabre-Kramer Pharmaceuticals.
Anita Clayton, M.D.: Grants: BioSante Pharmaceuticals, Inc., Palatin Technologies, Pfizer, Inc., Repligen Corporation, Takeda; Advisory Board Fee/Consultant Fee: Astellas Pharma US, Inc., Bayer, Dey Pharma, Eli Lilly and Company, Euthymics, Fabre-Kramer Pharmaceuticals, Forest, GlaxoSmithKline, Palatin Technoogies, Pfizer, Inc., Sunovion, Takeda Global Research & Development; Royalties/copyrights: Changes in Sexual Functioning Questionnaire, Guilford Publications.
Louis C. Smith, Ph.D.: consultant with Fabre-Kramer Pharmaceuticals.
Irwin Goldstein, M.D.: Consultant: Alagin Research, Aperture; Ad Board: Boehringer Ingelheim, Johnson & Johnson, Medtronic, Plethora Solutions, Vivus; Speaker: Auxilium, Bayer, BioSante, Coloplast, Eli Lilly, Pfizer, Timm Medical; Grant: Pfizer; Contract: Boehringer Ingelheim.
Leonard R. DeRogatis, Ph.D.: consultant and investigator with Boehringer-Ingelheim, BioSante Inc., Johnson & Johnson, and Fabre-Kramer Pharmaceuticals.
Supplemental Material

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share